Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
611 in chronic rhinosinusitis with nasal polyps
NCT06639295Phase 3Active, not recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing 611 with Placebo (2 arms). Primary endpoints: Bilateral Nasal Polyp Score at 24 weeks and Nasal Congestion Symptom Severity Score at 24 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
SSGJ-611
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT06639295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639295.